A randomized, phase III trial (“ADMIRAL”) was conducted in 14 countries and recruited 371 adult AML patients with FLT3-ITD or -TKD mutations who were refractory to prior chemotherapy [59]. The gene discussed is FLT3; the disease is acute myeloid leukemia.